|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.02 - 0.02|
|52 Week Range||0.02 - 0.38|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Avant Diagnostics, Inc. ("Avant" or the "Company") (AVDX), an oncology-focused healthcare technology company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, today announced newly appointed President & CEO Philippe Goix delivered an address to shareholders outlining his assessment of the Company's potential and the path forward the Company intends to take in order to succeed in commercializing and revamping the Company's proprietary technologies.
GAITHERSBURG, Maryland , July 18, 2017 /PRNewswire/ -- Two thirds of all breast cancer (BC) tumors are estrogen receptor positive (ER)+ ER+ BC patients have mixed responses to endocrine therapy Research ...
Avant Diagnostics, Inc. ("Avant") (AVDX), an oncology-focused Healthcare-IT company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, acquired an exclusive option to license the patient-delivery technology platform from Genetic Health Solution ("GHS", website: http://www.genetichealthsolution.com). GHS is a functional medicine practice that specializes in the aggregation and analysis of advanced biomarker testing data to provide tailored product recommendations for health optimization.
GAITHERSBURG, Maryland , June 27, 2017 /PRNewswire/ -- - Theralink predicts 5-year survival for patients in response to standard of care - Negative predictive value allows physicians to change treatment ...
GAITHERSBURG, Maryland , June 21, 2017 /PRNewswire/ -- Dr. Goix brings 20 years of successful healthcare commercialization experience Two posters were presented at ASCO June 3 rd , 2017 for Theralink® ...